|1.||Koeppen, S: 1 article (03/2004)|
|2.||Diener, H C: 1 article (03/2004)|
|3.||Postma, T J: 1 article (03/2004)|
|4.||Huijgens, P C: 1 article (03/2004)|
|5.||Körte, R: 1 article (03/2004)|
|6.||Scheulen, M E: 1 article (03/2004)|
|7.||Verstappen, C C P: 1 article (03/2004)|
|8.||Kiburg, B: 1 article (03/2004)|
|9.||Heimans, J J: 1 article (03/2004)|
|10.||Strumberg, D: 1 article (03/2004)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
11/01/1997 - "A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer."
03/01/1992 - "A group of 18 patients with ovarian cancer, who participated in an earlier randomized study with placebo or Org 2766, together with cisplatin and cyclophophamide, were thereafter prospectively followed up to 2 years after discontinuation of treatment to monitor the development of neurological signs and symptoms and vibration perception threshold (VPT). "
01/11/1990 - "In a randomized, double-blind, placebo-controlled study, we assessed the efficacy of an ACTH(4-9) analogue, Org 2766, in the prevention of cisplatin neuropathy in 55 women with ovarian cancer. "
11/01/1997 - "In this randomized, multicenter, double-blind, placebo-controlled study, 196 women with ovarian cancer were treated with cisplatin 75-100 mg/m2, cyclophosphamide 600-1000 mg/m2 plus placebo or two dose levels of Org 2766. "
11/01/1997 - "The objective was to evaluate the efficacy of Org 2766 (a hexapeptide analogue of ACTH) in the prevention or delay of cisplatin-induced neuropathy during chemotherapy in women with ovarian cancer as measured by vibration perception threshold (VPT). "
|2.||Peripheral Nervous System Diseases (PNS Diseases)
09/21/1990 - "We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the potential therapeutic efficacy of Org 2766 in this type of nerve damage. "
02/01/1989 - "This article documents the beneficial effect of the peptide Org 2766, an ACTH-(4-9) analogue, in diabetic peripheral neuropathy. "
04/01/1994 - "In this study we report a randomized double-blind, placebo-controlled trial to evaluate the effect of ORG 2766 in IDDM patients with peripheral neuropathy. "
11/01/1997 - "Instead of providing protection from and delay of onset of peripheral neuropathies caused by cisplatin, these results suggest that the administration of Org 2766 appears to cause an increase in the rate of change and degree of neuropathies (P > 0.05)."
02/01/1989 - "Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats."
|3.||Wounds and Injuries (Trauma)
09/21/1990 - "The finding that Org 2766 improved the quality of the repair following acrylamide neuropathy, together with previous studies showing beneficial effects in neuropathies caused by cisplatin or diabetes and after mechanical trauma, strongly suggests that Org 2766 may be beneficial in the treatment of various conditions in which the nervous system has sustained damage."
|4.||Testicular Neoplasms (Testicular Cancer)
06/01/1994 - "These results show that Org 2766 cannot completely prevent cisplatin neuropathy in young men with testicular cancer, but nerve damage may be ameliorated by the use of this ACTH (4-9) analogue."
06/01/1994 - "The efficacy of the ACTH (4-9) analogue Org 2766 in the prevention of subclinical cisplatin neuropathy was assessed in a double-blind placebo-controlled multi-centre study in patients with testicular cancer or adenocarcinoma of unknown primary. "
|3.||Adrenocorticotropic Hormone (ACTH)
|6.||Melanocyte-Stimulating Hormones (MSH)
|8.||Mifepristone (RU 486)
|10.||Glial Fibrillary Acidic Protein
|1.||Drug Therapy (Chemotherapy)